Boehringer Licenses Targets Resulting from Galapagos Collaboration

Boehringer Ingelheim has licensed a number of potential antiviral targets from Galapagos Genomics after identifying them using Galapagos’ gene knock-down technology, Galapagos said this week.

Scientists at Boehringer’s virology research center in Laval, Canada, used Galapagos’ SilenceSelect platform, a collection of adenoviruses with siRNA knock-down sequences targeting over 3,000 human transcripts, to identify a number of genes that influence viral replication in human cells.